GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GCAR-7213)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Global Coalition for Adaptive Research
Start Date
May 5, 2023
End Date
May 4, 2025
Administered By
Duke Cancer Institute
Awarded By
Global Coalition for Adaptive Research
Start Date
May 5, 2023
End Date
May 4, 2025